Lineage Cell Therapeutics/LCTX

$1.07

2.88%
-
1D1W1MYTD1YMAX

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing cell therapies to address unmet medical needs. It designs, develops, and manufactures specialized human cells with anatomical and physiological functions which are similar or identical to cells found naturally in the human body. It has five allogeneic product candidates: OpRegen, OPC1, VAC2, ANP1, and PNC1. OpRegen is a retinal pigment epithelium (RPE) cell replacement therapy in a Phase IIa development for the treatment of geographic atrophy secondary to age-related macular degeneration (AMD). OPC1 is an oligodendrocyte progenitor cell therapy in a Phase I/IIa development for the treatment of acute spinal cord injuries (SCI); VAC is a dendritic cell therapy produced from Lineages VAC technology platform for immuno-oncology and infectious disease, in Phase I clinical development for the treatment of non-small cell lung cancer.

Ticker

LCTX

Sector

Healthcare

Trading on

AMEX

Industry

Biotechnology & Drugs

CEO

Brian Culley

Employees

78

Headquarters

Carlsbad, United States

LCTX Metrics

BasicAdvanced
$194.13M
Market cap
-
P/E ratio
-$0.13
EPS
1.27
Beta
-
Dividend rate

What the Analysts think about LCTX

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 6 analysts.
351.4% upside
High $7.00
Low $2.00
$1.07
Current price
$4.83
Average price target

LCTX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-591.66% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$1.2M
-62.5%
Net income
$-7.1M
36.54%
Profit margin
-591.66%
264.1%

LCTX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 6.67%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.03
-$0.03
-$0.03
-$0.04
-
Expected
-$0.04
-$0.04
-$0.04
-$0.04
-$0.04
Surprise
-19.23%
-21.74%
-32.26%
-6.67%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Lineage Cell Therapeutics stock

Buy or sell Lineage Cell Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing